Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by dogwagon Oct 10, 2012 7:34pm

130 Views

Post# 20471012

RE: RE: COMPARING BRD TO SGR!!!!

KEWL2,I as just making comparison for this qtr.SGR is expandng also and has a production target of 115,000 to 125,000 ounce target for next year.The are xpanding their mill capacity also but I was just making a price comparison for this qtr.As I said,both are in a growth stage with SGR about a year ahead of BRD.They arevery siular ompanies in many ways.

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023